FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023011486> ?p ?o ?g. }

• W2023011486 abstract "Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DCNext generation sequencing technologies have greatly expanded our understanding of cancer genomes, epigenomes and transcriptomes. This knowledge, however, has not yet been effectively translated into improved cancer therapeutics, partly due to the inability of available therapeutic modalities to target the most promising cancer driver pathways. In contrast to other therapeutic approaches, the druggable universe is not limited with antisense technology as inhibitors can be rationally designed based on sequence information alone. Recent human clinical data has demonstrated potent activity of systemically-administered, unformulated, antisense oligonucleotides (ASOs) when targeted to liver expressed genes. However, robust activity in extra-heptatic tissues and tumors has been limited with existing ASO chemistries. Here we evaluate the activity of high affinity next generation (constrained ethyl) ASOs in extrahepatic tissues and tumors of multiple preclinical cancer models including spontaneous tumors, human tumor xenografts and several primary patient-derived xenograft models. As a test case we employed next generation ASOs to inhibit the difficult to drug transcription factor STAT3. ASOs targeting mouse STAT3 sequences and the human-specific STAT3 ASO (AZD9150) demonstrate potent and selective inhibition of target RNA and protein levels in tumors and tumor-associated stromal cells of a broad range of cancer models, resulting in strong antitumor activity in several models. These findings suggest that next generation ASO technology is now poised to become a key therapeutic modality to bridge the pharmacogenomic divide in cancer drug discovery. The STAT3 ASO inhibitor, AZD9150 is currently in human clinical studies including patients with lymphomas.Citation Format: Youngsoo Kim, Jeff Hsu, Tianyuan Zhou, Nancy Zhang, Richard Woessner, Murali VP Nadella, Deborah Lawson, Corinne Reimer, Guobin He, Joanna Schmidt, Xiaokun Xiao, Sarah Greenlee, Gourab Bhattacharjee, Gene Hung, Brett P. Monia, A. Robert MacLeod. Potent in vivo pharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-317. doi:10.1158/1538-7445.AM2013-LB-317" @default.
• W2023011486 created "2016-06-24" @default.
• W2023011486 creator A5004144404 @default.
• W2023011486 creator A5004266830 @default.
• W2023011486 creator A5005417801 @default.
• W2023011486 creator A5009399366 @default.
• W2023011486 creator A5013946717 @default.
• W2023011486 creator A5022335574 @default.
• W2023011486 creator A5037780629 @default.
• W2023011486 creator A5044334898 @default.
• W2023011486 creator A5049032346 @default.
• W2023011486 creator A5055402138 @default.
• W2023011486 creator A5066689916 @default.
• W2023011486 creator A5079071423 @default.
• W2023011486 creator A5084963518 @default.
• W2023011486 creator A5086348646 @default.
• W2023011486 creator A5087326265 @default.
• W2023011486 creator A5089741781 @default.
• W2023011486 date "2013-04-15" @default.
• W2023011486 modified "2023-09-25" @default.
• W2023011486 title "Abstract LB-317: Potentin vivopharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models." @default.
• W2023011486 doi "https://doi.org/10.1158/1538-7445.am2013-lb-317" @default.
• W2023011486 hasPublicationYear "2013" @default.
• W2023011486 type Work @default.
• W2023011486 sameAs 2023011486 @default.
• W2023011486 citedByCount "2" @default.
• W2023011486 countsByYear W20230114862013 @default.
• W2023011486 countsByYear W20230114862015 @default.
• W2023011486 crossrefType "proceedings-article" @default.
• W2023011486 hasAuthorship W2023011486A5004144404 @default.
• W2023011486 hasAuthorship W2023011486A5004266830 @default.
• W2023011486 hasAuthorship W2023011486A5005417801 @default.
• W2023011486 hasAuthorship W2023011486A5009399366 @default.
• W2023011486 hasAuthorship W2023011486A5013946717 @default.
• W2023011486 hasAuthorship W2023011486A5022335574 @default.
• W2023011486 hasAuthorship W2023011486A5037780629 @default.
• W2023011486 hasAuthorship W2023011486A5044334898 @default.
• W2023011486 hasAuthorship W2023011486A5049032346 @default.
• W2023011486 hasAuthorship W2023011486A5055402138 @default.
• W2023011486 hasAuthorship W2023011486A5066689916 @default.
• W2023011486 hasAuthorship W2023011486A5079071423 @default.
• W2023011486 hasAuthorship W2023011486A5084963518 @default.
• W2023011486 hasAuthorship W2023011486A5086348646 @default.
• W2023011486 hasAuthorship W2023011486A5087326265 @default.
• W2023011486 hasAuthorship W2023011486A5089741781 @default.
• W2023011486 hasConcept C104317684 @default.
• W2023011486 hasConcept C10679952 @default.
• W2023011486 hasConcept C121608353 @default.
• W2023011486 hasConcept C126322002 @default.
• W2023011486 hasConcept C16930146 @default.
• W2023011486 hasConcept C170734499 @default.
• W2023011486 hasConcept C2778923194 @default.
• W2023011486 hasConcept C502942594 @default.
• W2023011486 hasConcept C54355233 @default.
• W2023011486 hasConcept C60644358 @default.
• W2023011486 hasConcept C70721500 @default.
• W2023011486 hasConcept C71924100 @default.
• W2023011486 hasConcept C74187038 @default.
• W2023011486 hasConcept C86803240 @default.
• W2023011486 hasConcept C96232424 @default.
• W2023011486 hasConcept C98274493 @default.
• W2023011486 hasConceptScore W2023011486C104317684 @default.
• W2023011486 hasConceptScore W2023011486C10679952 @default.
• W2023011486 hasConceptScore W2023011486C121608353 @default.
• W2023011486 hasConceptScore W2023011486C126322002 @default.
• W2023011486 hasConceptScore W2023011486C16930146 @default.
• W2023011486 hasConceptScore W2023011486C170734499 @default.
• W2023011486 hasConceptScore W2023011486C2778923194 @default.
• W2023011486 hasConceptScore W2023011486C502942594 @default.
• W2023011486 hasConceptScore W2023011486C54355233 @default.
• W2023011486 hasConceptScore W2023011486C60644358 @default.
• W2023011486 hasConceptScore W2023011486C70721500 @default.
• W2023011486 hasConceptScore W2023011486C71924100 @default.
• W2023011486 hasConceptScore W2023011486C74187038 @default.
• W2023011486 hasConceptScore W2023011486C86803240 @default.
• W2023011486 hasConceptScore W2023011486C96232424 @default.
• W2023011486 hasConceptScore W2023011486C98274493 @default.
• W2023011486 hasLocation W20230114861 @default.
• W2023011486 hasOpenAccess W2023011486 @default.
• W2023011486 hasPrimaryLocation W20230114861 @default.
• W2023011486 hasRelatedWork W1587081454 @default.
• W2023011486 hasRelatedWork W1605152303 @default.
• W2023011486 hasRelatedWork W2016786373 @default.
• W2023011486 hasRelatedWork W2326075142 @default.
• W2023011486 hasRelatedWork W2337104664 @default.
• W2023011486 hasRelatedWork W2394358350 @default.
• W2023011486 hasRelatedWork W2394821131 @default.
• W2023011486 hasRelatedWork W2395791849 @default.
• W2023011486 hasRelatedWork W2486438979 @default.
• W2023011486 hasRelatedWork W2562640184 @default.
• W2023011486 hasRelatedWork W2613372445 @default.
• W2023011486 hasRelatedWork W2613944114 @default.
• W2023011486 hasRelatedWork W2739637516 @default.
• W2023011486 hasRelatedWork W2741933159 @default.
• W2023011486 hasRelatedWork W2885180194 @default.
• W2023011486 hasRelatedWork W2987694037 @default.
• W2023011486 hasRelatedWork W3083556024 @default.
• W2023011486 hasRelatedWork W3164636335 @default.
• W2023011486 hasRelatedWork W3179681232 @default.
• W2023011486 hasRelatedWork W619933310 @default.

• next